A new era in mental health treatment
Psychedelic-assisted therapy represents the most significant development in psychiatric treatment in decades. After a generation of stigma and legal restriction, rigorous clinical research has established compelling evidence for several psychedelic compounds — with ketamine already available, and psilocybin and MDMA in late-stage FDA trials.
Ketamine therapy: available now
Ketamine is currently the only legal psychedelic-assisted treatment available in the US. FDA-approved esketamine (Spravato) and off-label IV ketamine are used for treatment-resistant depression, with response rates of 50-70% in people who have failed multiple antidepressants. Effects are often rapid — within hours to days rather than weeks. Ketamine is available through psychiatrists and ketamine clinics nationwide.
Psilocybin therapy: in Phase 3 trials
Oregon and Colorado have legalized supervised psilocybin services. FDA Breakthrough Therapy designation for psilocybin-assisted therapy for major depression and treatment-resistant depression reflects compelling Phase 2 evidence. Phase 3 trials are ongoing. Current evidence shows significant reductions in depression and anxiety, including end-of-life anxiety in cancer patients.
MDMA-assisted therapy for PTSD
MDMA-assisted therapy for PTSD showed extraordinary Phase 3 results — 67% of participants no longer met PTSD criteria after treatment, compared to 32% for placebo. The FDA has requested additional studies before approval, but the evidence base is compelling. Treatment involves MDMA-assisted psychotherapy sessions in a clinical setting with trained therapists.
Be cautious of unregulated "psychedelic retreats" outside clinical settings. Legitimate psychedelic-assisted therapy involves medical screening, preparation sessions, closely supervised medicine sessions, and integration therapy. The therapeutic context — not just the compound — is central to outcomes.